ArticleWorld journal of gastroenterology2016
Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma.
Article in World journal of gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 3 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- The Role of PD-L1 Expression as a Predictive Biomarker in Esophageal Cancer: a Meta-Analysis.Journal of gastrointestinal cancer · 2026Pooled it
- Prognostic Value of Programmed Death Ligand-1 Expression in Solid Tumors Irrespective of Immunotherapy Exposure: A Systematic Review and Meta-Analysis.Molecular diagnosis & therapy · 2022Pooled it
- Pooled it
- Prognostic value of c-MET in oesophageal squamous cell carcinoma: a study based on the mRNA expression in TCGA database and a meta-analysis.Frontiers in medicine · 2025Article
- Significance of druggable targets (PD-L1, KRAS, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma.Diagnostic pathology · 2020Article
- MiR-212-3p mediates apoptosis and invasion of esophageal squamous cell carcinoma through inhibition of the Wnt/β-catenin signaling pathway by targeting SOX4.Journal of thoracic disease · 2020Article
- Programmed death ligand-1 expression in gastrointestinal cancer: Clinical significance and future challenges.Annals of gastroenterological surgery · 2020Review
- Significance of PD-L1 clones and C-MET expression in hepatocellular carcinoma.Oncology letters · 2019Article
- From Tumor Immunology to Immunotherapy in Gastric and Esophageal Cancer.International journal of molecular sciences · 2018Review
- Clinical relevance of PD-L1 and PD-L2 overexpression in patients with esophageal squamous cell carcinoma.Journal of thoracic disease · 2018Article
- Article
- Expression, regulation and targeting of receptor tyrosine kinases in esophageal squamous cell carcinoma.Molecular cancer · 2018Review
- PD-L1 Expression On tumor Cells Was Associated With Unfavorable Prognosis In Esophageal Squamous Cell Carcinoma.Journal of Cancer · 2018Article
- Programmed death ligand-1 and MET co-expression is a poor prognostic factor in gastric cancers after resection.Oncotarget · 2017Article
- Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading.Cell death & disease · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo investigate the expression and prognostic role of programmed death ligand-1 (PD-L1) in locally advanced esophageal squamous cell carcinoma (ESCC).
methodsA total of 200 patients with ESCC who underwent radical esophagectomy with standard lymphadenectomy as the initial definitive treatment in Seoul National University Hospital from December 2000 to April 2013 were eligible for this analysis. Tissue microarrays were constructed by collecting tissue cores from surgical specimens, and immunostained with antibodies directed against PD-L1, p16, and c-Met. Medical records were reviewed retrospectively to assess clinical outcomes. Patients were divided into two groups by PD-L1 status, and significant differences in clinicopathologic characteristics between the two groups were assessed.
resultsTumor tissues from 67 ESCC patients (33.5%) were PD-L1-positive. Positive p16 expression was observed in 21 specimens (10.5%). The H-score for c-Met expression was ≥ 50 in 42 specimens (21.0%). Although PD-L1-positivity was not significantly correlated with any clinical characteristics including age, sex, smoking/alcoholic history, stage, or differentiation, H-scores for c-Met expression were significantly associated with PD-L1-positivity (OR = 2.34, 95%CI: 1.16-4.72,
conclusionPD-L1 expression is positively correlated with c-Met expression in ESCC. PD-L1 may play a critical role in distant failure and progression of ESCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.